OR WAIT null SECS
September 02, 2023
There are many promising trials in the pipeline that may bring big news for major therapeutic areas.
September 01, 2023
Interpreting data and understanding the various components of biologic drug substance testing is an important skillset to know as a lab personnel.
August 31, 2023
The Centers for Medicare & Medicaid Services (CMS) has announced the first 10 drugs covered under Medicare Part D selected for negotiation.
Bristol Myers Squibb’s Reblozyl (luspatercept-aamt) is approved as a first-line treatment for anemia in adults with lower-risk myelodysplastic syndromes.
The updated vaccine will be ready to ship following a positive European Commission review.
August 30, 2023
This is the first biosimilar to Tysabri, an injection for adults with multiple sclerosis.
August 25, 2023
Adam Smith, a House of Representatives member representing Washington's 9th congressional district, discusses the state of U.S. healthcare and pharma.
August 24, 2023
The patent grants Alterity 20 years of exclusivity over a new class of iron chaperone drug candidates.
August 23, 2023
FDA has approved a new mAb therapy from Regeneron Pharmaceuticals as well as a higher dose version of Eylea, the company’s eye disease therapeutic.
The immunization, meant to protect infants aged six months or lower, is given to pregnant individuals at a gestation period of 32 to 36 weeks.